stockrowAlign Technology, Inc.
ALGN Healthcare Medical Instruments & Supplies
Align Technology, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.0 billion, up 0.90% from fiscal 2024.
- Revenue
- +1.92%
- EPS
- +143.9%
- Free cash flow
- +8.26%
Quarter to September 2026, against a year earlier
Follow ALGN
Alert me
Align Technology, Inc. (ALGN) Return on equity
Align Technology, Inc.'s return on equity over the twelve months to 30 September 2026 was 0.00%, down 10.4 percentage points from fiscal 2025 (10.4%). Over the past ten years it has ranged from 10.0% (fiscal 2022) to 77.6% (fiscal 2020); the current reading is higher than 18% of that period. That is in line with the Medical Instruments & Supplies industry median of 0.00% and above the Healthcare sector median of −26.3%.
Return on equity, annual
Embed this chart
Annual newest first
| Period | Return on equity | Change (points) |
|---|---|---|
| FY2025 | 10.4% | (0.87) |
| FY2024 | 11.3% | (1.05) |
| FY2023 | 12.3% | 2.30 |
| FY2022 | 10.0% | (12.51) |
| FY2021 | 22.5% | (55.03) |
| FY2020 | 77.6% | 43.48 |
| FY2019 | 34.1% | 0.82 |
| FY2018 | 33.3% | 11.72 |
| FY2017 | 21.5% | 0.95 |
| FY2016 | 20.6% | 2.59 |
Against its own ten years
Return on equity against peers
| Company | Return on equity |
|---|---|
| ATR AptarGroup, Inc. compare | 9.86% |
| COO The Cooper Companies, Inc. compare | 6.84% |
| AVTR Avantor, Inc. compare | 5.91% |
| SOLV Solventum Corporation compare | 3.19% |
| ALGN Align Technology, Inc. | 0.00% |
| RGEN Repligen Corporation compare | −0.57% |
| BLCO Bausch + Lomb Corporation compare | −1.71% |
| BAX Baxter International Inc. compare | −10.6% |
| TFX Teleflex Incorporated compare | −28.9% |
| Medical Instruments & Supplies industry median | 0.00% |
| Healthcare sector median | −26.3% |
| Market median | 0.51% |
What Return on equity is
ROE shows how much profit a company earns for its shareholders on the equity they have in the business.
Annual: Net Income Allotted to Shareholders ÷ Average Common Equity; TTM: Net Income Allotted to Shareholders ÷ Average Common Equity (latest quarter)
More on ALGN
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement